Empirical antibiotic therapy for ventilator-associated pneumonia

Joseph Swanson, Diana L. Wells

Research output: Contribution to journalReview article

12 Citations (Scopus)

Abstract

Ventilator-associated pneumonia (VAP) is the most common infectious complication in the intensive care unit. It can increase duration of mechanical ventilation, length of stay, costs, and mortality. Improvements in the administration of empirical antibiotic therapy have potential to reduce the complications of VAP. This review will discuss the current data addressing empirical antibiotic therapy and the effect on mortality in patients with VAP. It will also address factors that could improve the administration of empirical antibiotics and directions for future research.

Original languageEnglish (US)
Pages (from-to)339-351
Number of pages13
JournalAntibiotics
Volume2
Issue number3
DOIs
StatePublished - Jul 4 2013

Fingerprint

Ventilator-Associated Pneumonia
Anti-Bacterial Agents
Intensive care units
Mortality
Artificial Respiration
Intensive Care Units
Length of Stay
Therapeutics
Costs and Cost Analysis
Costs

All Science Journal Classification (ASJC) codes

  • Biochemistry
  • Microbiology
  • Infectious Diseases
  • Microbiology (medical)
  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Empirical antibiotic therapy for ventilator-associated pneumonia. / Swanson, Joseph; Wells, Diana L.

In: Antibiotics, Vol. 2, No. 3, 04.07.2013, p. 339-351.

Research output: Contribution to journalReview article

Swanson, Joseph ; Wells, Diana L. / Empirical antibiotic therapy for ventilator-associated pneumonia. In: Antibiotics. 2013 ; Vol. 2, No. 3. pp. 339-351.
@article{db93f45b3517454eb42f44574ca158b7,
title = "Empirical antibiotic therapy for ventilator-associated pneumonia",
abstract = "Ventilator-associated pneumonia (VAP) is the most common infectious complication in the intensive care unit. It can increase duration of mechanical ventilation, length of stay, costs, and mortality. Improvements in the administration of empirical antibiotic therapy have potential to reduce the complications of VAP. This review will discuss the current data addressing empirical antibiotic therapy and the effect on mortality in patients with VAP. It will also address factors that could improve the administration of empirical antibiotics and directions for future research.",
author = "Joseph Swanson and Wells, {Diana L.}",
year = "2013",
month = "7",
day = "4",
doi = "10.3390/antibiotics2030339",
language = "English (US)",
volume = "2",
pages = "339--351",
journal = "Antibiotics",
issn = "2079-6382",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "3",

}

TY - JOUR

T1 - Empirical antibiotic therapy for ventilator-associated pneumonia

AU - Swanson, Joseph

AU - Wells, Diana L.

PY - 2013/7/4

Y1 - 2013/7/4

N2 - Ventilator-associated pneumonia (VAP) is the most common infectious complication in the intensive care unit. It can increase duration of mechanical ventilation, length of stay, costs, and mortality. Improvements in the administration of empirical antibiotic therapy have potential to reduce the complications of VAP. This review will discuss the current data addressing empirical antibiotic therapy and the effect on mortality in patients with VAP. It will also address factors that could improve the administration of empirical antibiotics and directions for future research.

AB - Ventilator-associated pneumonia (VAP) is the most common infectious complication in the intensive care unit. It can increase duration of mechanical ventilation, length of stay, costs, and mortality. Improvements in the administration of empirical antibiotic therapy have potential to reduce the complications of VAP. This review will discuss the current data addressing empirical antibiotic therapy and the effect on mortality in patients with VAP. It will also address factors that could improve the administration of empirical antibiotics and directions for future research.

UR - http://www.scopus.com/inward/record.url?scp=85003756066&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85003756066&partnerID=8YFLogxK

U2 - 10.3390/antibiotics2030339

DO - 10.3390/antibiotics2030339

M3 - Review article

VL - 2

SP - 339

EP - 351

JO - Antibiotics

JF - Antibiotics

SN - 2079-6382

IS - 3

ER -